Clinical Trials Logo

Clinical Trial Summary

This is an open-label, single centre exploratory study to analyse brain exposure of AZD1390 in healthy volunteer males.


Clinical Trial Description

Up to 12 healthy male volunteers, 20 to 65 years of age will participate in the study. The study population chosen is sufficient to examine variability in pharmacokinetic and imaging measurements. All male volunteer subjects will have a baseline brain magnetic resonance imaging (MRI) for eligibility and anatomical delineation of brain regions to be applied in positron emission tomography (PET) image analysis. An arterial line will be inserted on day the healthy volunteer arrives for the administration of study drug and PET imaging (Day 1). The arterial line will be placed in the opposite arm than the one being used to administer the single intravenous microdose of [11C]AZD1390. Blood samples will be collected after the administration of microdose [11C]AZD1390 bolus injection and during the PET imaging procedure. The arterial line will be removed at the conclusion of the PET imaging study after the last blood sample has been collected. Standard institutional procedures will be followed for arterial line removal. The study will conclude with a telephone follow-up call within 7 business days after the PET measurement. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03215381
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 1
Start date October 10, 2017
Completion date February 19, 2018